Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC

This study is a single arm, open, multicenter phase II study. The main purpose of this study was to evaluate preliminary efficacy and safety of Tislelizumab combined with thoracic radiotherapy as first line therapy for Extensive stage small cell lung cancer.

Trial Details

NCT ID
NCT06536868
Phase
PHASE2
Sponsor
Second Hospital of Shanxi Medical University
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Tislelizumab
  • Etoposide
  • Carboplatin or Cisplatin
  • Thoracic radiotherapy
Locations (sample)
  • Jincheng, Shanxi, China|35.50222,112.83278
  • Jinzhong, Shanxi, China|37.68403,112.75471
  • Taiyuan, Shanxi, China|37.86944,112.56028
  • Taiyuan, Shanxi, China|37.86944,112.56028
  • Taiyuan, Shanxi, China|37.86944,112.56028

Key Eligibility Criteria

  • Patients aged between 18 to 80 years old (inclusive of 18th and 80th birthdays), male or female, at the time of signing the informed consent form;
  • Confirmed small cell lung cancer of extensive stage by histology or cytology;
  • At least one measurable lesion by imaging studies (according to RECIST 1.1) with a long diameter of ≥10 mm as examined by spiral CT or MRI;
  • Within 3 days prior to treatment, an ECOG score of 0 to 1;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →